---
schema_version: "secwatch.filing_event.v1"
accession: "0001129928-26-000028"
form_type: "8-K"
ticker: "ONCY"
cik: "0001129928"
company_name: "ONCOLYTICS BIOTECH INC"
filed_at: "2026-05-04T23:59:59+00:00"
generated_at: "2026-05-14T23:49:47.105923+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Oncolytics reports 19.5-month median DOR in 2L RAS-mutant MSS mCRC; triples ORR vs SOC

## Summary
- Pelareorep-based combo shows median duration of response 19.5 months in 2L KRAS-mutant MSS mCRC, vs historical 4–6 months.
- Objective response rate 33% with pelareorep+FOLFIRI+bevacizumab, tripling the 6-11% standard of care.
- Company actively engaging FDA to support potential accelerated approval pathway in this indication.
- REO 022 study continues enrollment in randomized Phase 2 for 2L RAS-mutant MSS mCRC.
- Data highlight durable benefit in a difficult-to-treat colorectal cancer population with few options.

## SEC filing metadata
- accession: 0001129928-26-000028
- form_type: 8-K
- ticker: ONCY
- cik: 0001129928
- company_name: ONCOLYTICS BIOTECH INC
- filed_at: 2026-05-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1129928/000112992826000028/0001129928-26-000028-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1129928/000112992826000028/oncy-20260504.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001129928-26-000028
- JSON: https://secwatch.observer/filing/0001129928-26-000028.json
- Plain text: https://secwatch.observer/filing/0001129928-26-000028.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.